Diagnostics & imaging AI · Chest CT/X-ray AI
Riverain Technologies
Riverain Technologies builds FDA-cleared ClearRead AI for chest CT and X-ray to support detection of lung disease and more efficient thoracic reads. It is not an MRI acceleration product or multi-ology triage marketplace.
Strong fit
- Hospitals and imaging centers focused on lung nodule and chest disease detection on CT and X-ray
- Programs that will measure detection performance and reading-time impact after ClearRead goes live
- Buyers comparing FDA-cleared thoracic AI rather than multi-ology triage platforms
Weak fit
- Sites whose primary buy is stroke/PE multi-ology triage orchestration
- Buyers without chest CT or XR volume to justify the module
- Teams that only need acquisition-speed enhancement (Subtle lane)
Bottom line
Riverain Technologies earns a Recommend for imaging programs that care about chest CT and X-ray detection with ClearRead tools more than a broad triage marketplace. FDA-cleared ClearRead products and a long thoracic focus are the center of the story. Outcomes depend on radiologist trust, false-positive handling, and whether reads stay in the native viewer. Product depth is narrower than Aidoc's multi-ology platform and different from Subtle's acceleration thesis. Implementation is a PACS-integrated clinical AI project. Pricing is custom. Third-party revenue estimates sit roughly $6-12M. Score sits with Studycast on our diagnostics board for specialty imaging AI buyers.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Riverain Technologies builds FDA-cleared ClearRead AI for chest CT and X-ray to support earlier detection of lung disease and more efficient thoracic reads.
Compare Aidoc or Avicenna when you need multi-finding CT triage, Subtle when the job is scan acceleration, and Koios when the modality is ultrasound CDS rather than chest CT/XR.
Score reflects solid specialty thoracic AI marks on our diagnostics board.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Riverain Technologies | 7.3 | 6.9 |
| Subtle Medical | 7.2 | 6.8 |
| Aidoc | 7.9 | 7.5 |
| DeepTek | 7.1 | 6.8 |
| Avicenna.AI | 6.9 | 6.6 |
| Studycast | 7.2 | 6.9 |
| Koios Medical | 6.7 | 6.3 |
| AISAP | 7.0 | 6.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Software licensing for ClearRead CT/X-ray modules; site and volume based. |
| What usually drives cost | Sites, modalities (CT vs XR), volume, and deployment path (clinic vs cloud). |
| What to ask in diligence | Cost at your chest CT/XR volume, FDA indication coverage, and PACS integration scope. |
| Published pricing | Public list price: not published. Expect a clinical imaging AI quote. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Riverain Technologies to function | |
| Radiology clinical owner plus imaging IT | AI tools fail without both. |
| PACS/RIS/EMR interface path documented | Orphan results queues create safety risk. |
| Agreement on which exam types are in scope | Boiling the ocean delays value. |
| Alert or enhanced-series review staffing plan | Unowned queues become ignored queues. |
| Change control for clinical downtime windows | Surprise viewers during peak lists destroy trust. |
| What will maximize your value | |
| Measure turnaround, reopen rates, or detection metrics named at kickoff | Demo accuracy is not operations. |
| Start with one high-volume exam family | Narrow wins beat empty enterprise banners. |
| Review false positives weekly with radiologists | Noisy tools get turned off. |
| Keep radiologists in native viewers when possible | Extra worklists kill adoption. |
| Document FDA indication coverage vs your protocol mix | Mismatched clearances waste spend. |
| Deal-breakers | |
| No imaging IT or clinical owner. | |
| You refuse any interface work. | |
| You expect ambient scribe outcomes from imaging AI. | |
| Nobody will review alerts or enhanced series. | |
| Legal blocks cloud or vendor PHI paths you require. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope | 2–4 weeks — Exam list, interfaces, success metrics. |
| 2 | Integrate | 4–12 weeks — PACS/RIS/EMR hooks; validation cases. |
| 3 | Pilot | 4–8 weeks — One site or modality family. |
| 4 | Expand | Ongoing — More sites; tuning. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.